Urologix (ULGX) 0.0900 $ULGX
Urologix Announces SEC Deregistration
GlobeNewswire - Thu Jul 09, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced its decision to terminate and suspend the registration of its stock with the Securities and Exchange Commission (the "SEC"
. The Company also intends to cause its common stock to cease trading on the OTCQB and commence trading on the OTC Pink marketplace. For more information about the OTC Pink marketplace, please see www.otcmarkets.com.
Costs for In-Office BPH Therapies Presented at the AUA 2015 Annual Meeting in New Orleans
GlobeNewswire - Thu May 21, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX), a market leader for the in-office treatment of benign prostatic hyperplasia (BPH) today announced that data highlighting the costs and outcomes of cooled high energy Transurethral Microwave Therapy (HE-TUMT), Transurethral Needle Ablation (TUNA), and the Prostatic Urethral Lift (PUL) were the topic of a podium presentation this past weekend at the American Urological Association (AUA) 2015 Annual Meeting held in New Orleans, LA.
Urologix's (ULGX) CEO Greg Fluet on Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 6:40PM CDT
Urologix Products Featured in Cost-Effectiveness Research to be Presented at Upcoming Industry Meeting in New Orleans
GlobeNewswire - Tue May 12, 3:01PM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced an upcoming presentation at the American Urological Association (AUA) 2015 annual meeting to be held May 15-18, 2015 in New Orleans, LA.
Next Week In Biotech: ASCO Abstracts, Pernix PDUFA, Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri May 08, 8:00AM CDT
Biotech investors have plenty to look forward to next week, as the American Society of Clinical Oncology will release presentation abstracts for its upcoming annual meeting, while a PDUFA date is expected for Pernix (NASDAQ: PTX ). Last week's flood...
ARWR: 6.68 (+0.07), CLSN: 2.30 (+0.10), CMRX: 46.90 (+1.08), SCLN: 9.02 (-0.52), ELOS: 10.35 (+0.49), ZGNX: 15.17 (+1.95), LGND: 99.72 (+0.46), DEPO: 30.14 (+2.03), IMUC: 0.49 (+0.01), ARGS: 6.45 (+0.69), OPXA: 0.44 (-0.01), FLML: 21.76 (+0.72), OGXI: 2.23 (+0.13), CTSO: 6.20 (+0.40), DARA: 0.88 (+0.01), ICCC: 9.07 (+0.51), ICPT: 247.71 (+4.45), PBYI: 106.25 (-2.12), BDSI: 8.64 (+0.15), ACT: 298.98 (-2.94), DRNA: 12.61 (+0.31), BSTC: 50.96 (-0.51), PAHC: 38.43 (+1.08), PTX: 5.39 (+0.01), XON: 46.54 (+1.02), FOMX: 11.18 (+0.22), CLDN: 1.26 (+0.01), BIOC: 2.60 (-0.01), CHRS: 33.06 (+3.19), DSCI: 6.94 (+0.09), INO: 7.46 (+0.19), FMI: 33.17 (+0.82), CYTX: 0.47 (+0.01), ANTH: 8.32 (+0.85), ATHX: 1.14 (-0.01), ALQA: 5.19 (+0.09), ENDP: 83.12 (+2.66), DPLO: 48.64 (+1.85), GALT: 2.67 (+0.12), RPRX: 7.54 (+0.24), OMER: 17.33 (+0.29), HALO: 22.78 (+0.38), IDRA: 3.49 (+0.05), CF: 61.71 (+0.91), BTX: 3.51 (-0.13), APRI: 1.76 (+0.01), ATRS: 2.26 (+0.09), KPTI: 25.57 (+0.24)
Urologix to Host Its Fiscal Year 2015 Third Quarter Conference Call
GlobeNewswire - Tue May 05, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present third quarter fiscal year 2015 results on Tuesday, May 12, 2015 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-877-359-9508 and enter the conference ID 42703418 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
New finance chief at Urologix
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 11:41AM CDT
Urologix Announces Hiring of Chief Financial Officer
GlobeNewswire - Mon Mar 23, 8:00AM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the appointment of Scott M. Madson as its Chief Financial Officer effective April 1, 2015. Mr. Madson brings over 30 years of both public and private company financial leadership experience to his new role, having most recently provided finance and accounting management consulting services through his company, Madson Consulting LLC. Previously, Scott was Vice President, Controller and Chief Accounting Officer for Universal Hospital Services, Inc, one of the nation's largest providers of mobile medical equipment and healthcare technology management services.
Urologix to Host Its Fiscal Year 2015 Second Quarter Conference Call
GlobeNewswire - Thu Jan 29, 3:00PM CST
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present second quarter fiscal year 2015 results on Thursday, February 5, 2015 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-515-2910 and enter the Participant Passcode 37953871 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Urologix reports February 5
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:08AM CST
Urologix reports FQ1 loss
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:40PM CST
Urologix to Host Its Fiscal Year 2015 First Quarter Conference Call
GlobeNewswire - Tue Oct 28, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present first quarter fiscal year 2015 results on Tuesday, November 4, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-318-8617 and enter the Participant Passcode 57661939 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
VigiLanz Names Patrick Spangler as Chief Financial Officer
Business Wire - Tue Sep 09, 7:00AM CDT
VigiLanz, a digital healthcare technology company headquartered in Minneapolis, announced today the appointment of Patrick Spangler as Chief Financial Officer.
Ablation Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
M2 - Wed Aug 13, 10:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4s4mvw/ablation) has announced the addition of the "Ablation Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. An ablation procedure is a minimally invasive process to remove unwanted tissue from the body by using various energy devices such as radiofrequency, microwave, ultrasound, electrical current, laser and others. The ablation devices are consisting of catheters, generators and other monitoring equipments. Ablation technologies are majorly employed for surgical procedures in cardiological disorders such as atrial fibrillation, arrhythmia, refractory hypertension and others; along with this, removal of cancerous and non cancerous tumors is also important application of ablation devices. As ablation surgeries are minimally invasive nature, it reduces post surgical complications and gives more accurate and successful results, therefore market for ablation technologies have high growth potential in coming future. Global ablation technologies market is analyzed on the basis of technologies and applications. The technology component is further segmented into six major categories namely radiofrequency (RF), cryotherapy, ultrasound or High Intensity Focused Ultrasound (HIFU), light or laser, electrical, microwave and others. Whereas, the market by application is subcategorized into cardiology (includes renal denervation), gynecological (includes endometrial ablation), oncology, pain management, urology, ophthalmology (includes LASIK) and others. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Ablation Technologies Market, by Application Chapter 5 Global Ablation Technologies Market, by Technology Chapter 6 Global Ablation Technologies Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - AngioDynamics, Inc. - AtriCure, Inc. - BSD Medical Corporation - Biosense Webster Inc. - Boston Scientific Corporation - Covidien plc - Medtronic, Inc. - St. Jude Medical, Inc. - Urologix, Inc. For more information visit http://www.researchandmarkets.com/research/4s4mvw/ablation
BSX: 17.60 (+0.15), MDT: 74.37 (+1.28), STJ: 75.33 (+0.79), BSDM: 0.62 (+0.13), ATRC: 24.31 (+0.89)
Urologix Announces SEC Deregistration
GlobeNewswire - Thu Jul 09, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced its decision to terminate and suspend the registration of its stock with the Securities and Exchange Commission (the "SEC"
. The Company also intends to cause its common stock to cease trading on the OTCQB and commence trading on the OTC Pink marketplace. For more information about the OTC Pink marketplace, please see www.otcmarkets.com. Costs for In-Office BPH Therapies Presented at the AUA 2015 Annual Meeting in New Orleans
GlobeNewswire - Thu May 21, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX), a market leader for the in-office treatment of benign prostatic hyperplasia (BPH) today announced that data highlighting the costs and outcomes of cooled high energy Transurethral Microwave Therapy (HE-TUMT), Transurethral Needle Ablation (TUNA), and the Prostatic Urethral Lift (PUL) were the topic of a podium presentation this past weekend at the American Urological Association (AUA) 2015 Annual Meeting held in New Orleans, LA.
Urologix's (ULGX) CEO Greg Fluet on Q3 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 6:40PM CDT
Urologix Products Featured in Cost-Effectiveness Research to be Presented at Upcoming Industry Meeting in New Orleans
GlobeNewswire - Tue May 12, 3:01PM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced an upcoming presentation at the American Urological Association (AUA) 2015 annual meeting to be held May 15-18, 2015 in New Orleans, LA.
Next Week In Biotech: ASCO Abstracts, Pernix PDUFA, Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri May 08, 8:00AM CDT
Biotech investors have plenty to look forward to next week, as the American Society of Clinical Oncology will release presentation abstracts for its upcoming annual meeting, while a PDUFA date is expected for Pernix (NASDAQ: PTX ). Last week's flood...
ARWR: 6.68 (+0.07), CLSN: 2.30 (+0.10), CMRX: 46.90 (+1.08), SCLN: 9.02 (-0.52), ELOS: 10.35 (+0.49), ZGNX: 15.17 (+1.95), LGND: 99.72 (+0.46), DEPO: 30.14 (+2.03), IMUC: 0.49 (+0.01), ARGS: 6.45 (+0.69), OPXA: 0.44 (-0.01), FLML: 21.76 (+0.72), OGXI: 2.23 (+0.13), CTSO: 6.20 (+0.40), DARA: 0.88 (+0.01), ICCC: 9.07 (+0.51), ICPT: 247.71 (+4.45), PBYI: 106.25 (-2.12), BDSI: 8.64 (+0.15), ACT: 298.98 (-2.94), DRNA: 12.61 (+0.31), BSTC: 50.96 (-0.51), PAHC: 38.43 (+1.08), PTX: 5.39 (+0.01), XON: 46.54 (+1.02), FOMX: 11.18 (+0.22), CLDN: 1.26 (+0.01), BIOC: 2.60 (-0.01), CHRS: 33.06 (+3.19), DSCI: 6.94 (+0.09), INO: 7.46 (+0.19), FMI: 33.17 (+0.82), CYTX: 0.47 (+0.01), ANTH: 8.32 (+0.85), ATHX: 1.14 (-0.01), ALQA: 5.19 (+0.09), ENDP: 83.12 (+2.66), DPLO: 48.64 (+1.85), GALT: 2.67 (+0.12), RPRX: 7.54 (+0.24), OMER: 17.33 (+0.29), HALO: 22.78 (+0.38), IDRA: 3.49 (+0.05), CF: 61.71 (+0.91), BTX: 3.51 (-0.13), APRI: 1.76 (+0.01), ATRS: 2.26 (+0.09), KPTI: 25.57 (+0.24)
Urologix to Host Its Fiscal Year 2015 Third Quarter Conference Call
GlobeNewswire - Tue May 05, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present third quarter fiscal year 2015 results on Tuesday, May 12, 2015 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-877-359-9508 and enter the conference ID 42703418 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
New finance chief at Urologix
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 11:41AM CDT
Urologix Announces Hiring of Chief Financial Officer
GlobeNewswire - Mon Mar 23, 8:00AM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the appointment of Scott M. Madson as its Chief Financial Officer effective April 1, 2015. Mr. Madson brings over 30 years of both public and private company financial leadership experience to his new role, having most recently provided finance and accounting management consulting services through his company, Madson Consulting LLC. Previously, Scott was Vice President, Controller and Chief Accounting Officer for Universal Hospital Services, Inc, one of the nation's largest providers of mobile medical equipment and healthcare technology management services.
Urologix to Host Its Fiscal Year 2015 Second Quarter Conference Call
GlobeNewswire - Thu Jan 29, 3:00PM CST
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present second quarter fiscal year 2015 results on Thursday, February 5, 2015 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-515-2910 and enter the Participant Passcode 37953871 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Urologix reports February 5
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 11:08AM CST
Urologix reports FQ1 loss
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:40PM CST
Urologix to Host Its Fiscal Year 2015 First Quarter Conference Call
GlobeNewswire - Tue Oct 28, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present first quarter fiscal year 2015 results on Tuesday, November 4, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-318-8617 and enter the Participant Passcode 57661939 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
VigiLanz Names Patrick Spangler as Chief Financial Officer
Business Wire - Tue Sep 09, 7:00AM CDT
VigiLanz, a digital healthcare technology company headquartered in Minneapolis, announced today the appointment of Patrick Spangler as Chief Financial Officer.
Ablation Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
M2 - Wed Aug 13, 10:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4s4mvw/ablation) has announced the addition of the "Ablation Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. An ablation procedure is a minimally invasive process to remove unwanted tissue from the body by using various energy devices such as radiofrequency, microwave, ultrasound, electrical current, laser and others. The ablation devices are consisting of catheters, generators and other monitoring equipments. Ablation technologies are majorly employed for surgical procedures in cardiological disorders such as atrial fibrillation, arrhythmia, refractory hypertension and others; along with this, removal of cancerous and non cancerous tumors is also important application of ablation devices. As ablation surgeries are minimally invasive nature, it reduces post surgical complications and gives more accurate and successful results, therefore market for ablation technologies have high growth potential in coming future. Global ablation technologies market is analyzed on the basis of technologies and applications. The technology component is further segmented into six major categories namely radiofrequency (RF), cryotherapy, ultrasound or High Intensity Focused Ultrasound (HIFU), light or laser, electrical, microwave and others. Whereas, the market by application is subcategorized into cardiology (includes renal denervation), gynecological (includes endometrial ablation), oncology, pain management, urology, ophthalmology (includes LASIK) and others. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Ablation Technologies Market, by Application Chapter 5 Global Ablation Technologies Market, by Technology Chapter 6 Global Ablation Technologies Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - AngioDynamics, Inc. - AtriCure, Inc. - BSD Medical Corporation - Biosense Webster Inc. - Boston Scientific Corporation - Covidien plc - Medtronic, Inc. - St. Jude Medical, Inc. - Urologix, Inc. For more information visit http://www.researchandmarkets.com/research/4s4mvw/ablation
BSX: 17.60 (+0.15), MDT: 74.37 (+1.28), STJ: 75.33 (+0.79), BSDM: 0.62 (+0.13), ATRC: 24.31 (+0.89)
